Alnylam Pharmace. buy DropStone
Start price
03.11.20
/
50%
€111.28
Target price
04.11.21
-
Performance (%)
-6.56%
End price
06.01.21
€103.98
Summary
This prediction ended on 06.01.21 with a price of €103.98. With a performance of -6.56%, the BUY prediction for Alnylam Pharmace. by DropStone closed slightly in the red. DropStone has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -1.233% | -1.233% | 36.780% | 45.135% |
| iShares Core DAX® | 3.075% | 0.488% | 11.388% | 50.357% |
| iShares Nasdaq 100 | 2.876% | 0.081% | 22.472% | 81.104% |
| iShares Nikkei 225® | 5.981% | 3.033% | 41.000% | 59.466% |
| iShares S&P 500 | 2.231% | 0.046% | 18.100% | 60.472% |
Comments by DropStone for this prediction
In the thread Alnylam Pharmace. diskutieren
Buy Alnylam Pharmace.